Vol. 1 No. 5 (2026), Articles
Vol. 1 No. 5 (2026)

LITERATURE REVIEW ON OPTIMIZING THE DIAGNOSTICS OF PATIENTS WITH METABOLIC ASSOCIATED STEATOHEPATITIS

Articles
Published 2026-05-22
Mamajonov Islombek
1st-year Master’s Student, Therapy Program Andijan State Medical Institute
PDF

Keywords

MASLD, MASH, steatohepatitis, liver fibrosis, non-invasive tests, FIB-4, elastography, MRI-PDFF, MRE, ELF, PRO-C3.

How to Cite

Mamajonov Islombek. (2026). LITERATURE REVIEW ON OPTIMIZING THE DIAGNOSTICS OF PATIENTS WITH METABOLIC ASSOCIATED STEATOHEPATITIS. Journal of Scientific Research of Uzbek Scholars, 1(5), 141-147. https://innopublication.com/index.php/jsrus/article/view/561
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Metabolic dysfunction–associated steatohepatitis (MASH) is the progressive inflammatory form within the spectrum of metabolic dysfunction–associated steatotic liver disease (MASLD), strongly linked to fibrosis progression, cirrhosis and hepatocellular carcinoma. Terminology and diagnostic strategies have recently evolved, shifting the focus toward early identification of “at-risk” patients (≥F2 fibrosis) through non-invasive tests (NITs), appropriate referral pathways, and longitudinal monitoring. This review summarizes evidence on MASH pathogenesis and clinical phenotypes, blood-based scores (FIB-4, NFS), elastography (VCTE), MRI-based tools (MRI-PDFF, MRE), serum biomarkers (ELF, PRO-C3), and combined diagnostic algorithms. A pragmatic stepwise optimization model is proposed: risk stratification → secondary assessment → specialist referral. 

PDF

References

1. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F. va boshq. A multisociety Delphi consensus statement on new fatty liver disease nomenclature // Hepatology. – 2023. – Vol. 78, № 6. – P. 1966–1986. – DOI: 10.1097/HEP.0000000000000520.

2. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) // Journal of Hepatology. – 2024. – Vol. 81, № 3. – P. 492–542. – DOI: 10.1016/j.jhep.2024.04.031.

3. Rinella M.E., Neuschwander-Tetri B.A., Caldwell S.H. va boshq. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease // Hepatology. – 2023. – Vol. 77, № 5. – P. 1797–1835. – DOI: 10.1097/HEP.0000000000000323.

4. Castera L., Rinella M.E., Tsochatzis E.A. Noninvasive Assessment of Liver Fibrosis // The New England Journal of Medicine. – 2025. – Vol. 393, № 17. – P. 1715–1729. – DOI: 10.1056/NEJMra2403308.

5. Younossi Z.M., Golabi P., de Avila L. va boshq. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review // Hepatology. – 2023. – Vol. 77, № 4. – P. 1335–1347. – DOI: 10.1097/HEP.0000000000000004.

6. Feng G., Wang X. va boshq. Global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) using Global Burden of Disease data (2010–2021) // JHEP Reports. – 2025. – (maqola ma’lumotlari bo‘yicha).

7. Angulo P., Hui J.M., Marchesini G. va boshq. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD // Hepatology. – 2007. – Vol. 45, № 4. – P. 846–854. – DOI: 10.1002/hep.21496.

8. Sterling R.K., Lissen E., Clumeck N. va boshq. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection (FIB-4) // Hepatology. – 2006. – Vol. 43, № 6. – P. 1317–1325. – DOI: 10.1002/hep.21178.

9. Karlas T., Petroff D., Sasso M. va boshq. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis // Journal of Hepatology. – 2017. – Vol. 66, № 5. – P. 1022–1030. – DOI: 10.1016/j.jhep.2016.12.022.

10. Vali Y., Lee J., Boursier J. va boshq. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in NAFLD: a systematic review and meta-analysis // Journal of Hepatology. – 2020. – (son/raqamlar bo‘yicha). – DOI: 10.1016/S0168-8278(20)30198-7.

11. Boyle M., Tiniakos D., Schattenberg J.M. va boshq. Performance of the PRO-C3 collagen neo-epitope biomarker in the diagnosis of advanced fibrosis in NAFLD // Journal of Hepatology. – 2019. – Vol. 71. – (betlar).

12. Mózes F.E., Lee J.A., Selvaraj E.A. va boshq. Performance of non-invasive tests and histology for the prediction of clinical outcomes in NAFLD (IPD meta-analysis) // The Lancet Gastroenterology & Hepatology. – 2023. – (son/raqamlar bo‘yicha).

13. Woreta T.A., Liu Y., Dizechi S. va boshq. Validation of the accuracy of the FAST score for identifying patients with at-risk NASH // (PMC manbasi bo‘yicha). – 2022.

14. Stine J.G., Munaganuru N., Barnard A. va boshq. Change in MRI-PDFF and histologic response in patients with NASH: a systematic review and meta-analysis // Clinical Gastroenterology and Hepatology. – 2021. – (son/raqamlar).

15. U.S. Food and Drug Administration (FDA). FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease (Rezdiffra/resmetirom) // Press-announcement. – 14.03.2024.